



Making Lives Safer Through

# NANOTECHNOLOGY

KEEPING SURFACES CLEAN

Corporate Presentation

CSE: FNDX | OTCQB: FDXTF | FSE: E8D

AUGUST 2024



# Forward-Looking Statement

This presentation contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; expectations regarding industry trends, including with respect to the antimicrobial surface and coating market, overall market growth rates and the Company's growth rates and growth strategies; that microbe repellent technology is a promising, high-growth industry; the use of available funds; the performance of the Company's business and operations; the Company's expectations regarding revenues, expenses and anticipated cash needs; the intention to grow the Company's business, product pipeline and operations; the expected timing and completion of the Company's near-term objectives; the expected timing and achievement of commercial launch of REPELWRAP™ film in 2H2024 and for other products; laws and regulations and any amendments thereto applicable to the Company; the Company's competitive advantages and business and growth strategies; the Company's future product offerings, including potential new applications (i.e. catheters) and new formulations (i.e. spray); the Company's research and development initiatives and expected results thereof; the Company's growing patent portfolio; the Company entering into distribution, manufacturing and other business relationships, in Canada, the United States, and globally; the potential of the Company's technology to protect against the spread of pathogens on surfaces through repelling bacteria and viruses that come in contact with its surface; that the Company's technology will bring significant value in controlling the spread of surface borne infectious diseases; trends regarding healthcare-acquired infections; the Company's ability to access multi-million-dollar markets; proprietary REPELWRAP™ film and/or spray could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help prevent pathogen transmission; the Company's nanotechnology has the potential to be applied to other types of surfaces and materials – such as catheters which could significantly help reduce blockages caused by bacterial colony and/or blood clot formation in long-use catheters and that underserved markets like this offer potentially future upside, if the Company can successfully adapt their technology; the Company's intention to initially target REPELWRAP™ film towards healthcare settings and high traffic public touchpoints; that as the Company continues its product development, we may see it used to protect surfaces in other high traffic places like the transportation, education, sports and entertainment sectors; the growing global commitment to reduce the spread of pathogens; the development of the Company's spray nanotechnology, which could be easier to apply to many surfaces and expand potential market applications; the Company's organic growth strategy and expansion strategy; line extensions for REPELWRAP™ film; development of a nano-coating for catheters and further development of core technology as well as into additional applications; expansion into vertical markets; licensing of additional nanotechnology formulations and/or complementary products that reduce pathogen spread; potential licensing, M&A and partnerships within the infectious disease space; and that REPELWRAP™ film and/or spray will provide additional protection to current disinfecting practices to control the spread of pathogens.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history, no revenues and uncertainty around additional financing; negative cash flow history; no production history and lack of revenues from sales; no history of manufacturing or distribution; highly competitive industry; satisfying the terms of the License Agreement, Spray License Agreement and Collaborative Research Agreements between the Company and McMaster University and maintaining licenses in good standing; inability of McMaster University to satisfy the terms under the License Agreement, Spray License Agreement and Collaborative Research Agreements; ability to successfully complete scale-up and development of commercial film, spray or other products; research and development activities; reliance on grant funding; limited number of products; dependence on collaborative partners, licensors and others; no formal manufacturing or distribution agreements in place; changes and restrictions due to legal and regulatory requirements; dependence on each product's acceptance in the market; possibility of smaller market opportunities than anticipated; increasing regulatory and compliance costs for public companies; global economic instability; product liability claims and lawsuits; system failures; reliance on management and loss of key employees or inability to hire key personnel; limited experience of senior management in managing a public company; fraudulent or illegal activity by employees, contractors and consultants; inability to effect service of process on some of the Company's directors and officers; management's efforts and abilities; potential conflicts of interest; inability to protect intellectual property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary rights of third parties; risks related to forward-looking information; volatility of the market price of the Company's common shares; potential dilution of the common shares; lack of an active, liquid and orderly trading market for the common shares; failure of securities or industry analysts to publish research or publish inaccurate or unfavourable research about the Company; inability or unwillingness to pay dividends; exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public health crisis or another global health pandemic; use of available funds; effect of general economic and political conditions; internal controls; and other risk factors set forth in the Company's public filings, publicly available through the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) at [www.sedarplus.ca](http://www.sedarplus.ca). The reader is urged to refer to the Company's prospectus and other filings, publicly available through SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any Forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement.

While the information contained in this presentation is believed to be accurate, the Company expressly disclaims any and all liability for any losses, claims or damages of whatsoever kind based upon the information contained in, or omissions from, this presentation or any oral communication transmitted in connection therewith. In addition, none of the statements contained in this presentation are intended to be, nor shall be deemed to be, representations or warranties of the Company. Where the information is from third-party sources, the information is from sources believed to be reliable, but the Company has not independently verified any of such information contained herein.

This presentation is not, and under no circumstances is to be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of securities. Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any securities.

## DEVELOPING INNOVATIVE NANOCOATINGS TO PROTECT SURFACES FROM LETHAL PATHOGENS

- REPEL bacteria, viruses and liquids
- REDUCE spread of bacteria & viruses

# The Problem

## Spread of pathogens is hard to control

- Current disinfecting practices are not enough
- One of the top 10 causes of death in the U.S.<sup>1,2</sup>
- ~98,000 deaths; costing ~\$28 Bn annually in U.S. <sup>2, 3</sup>
- Most bacteria are resistant to antibiotics making them difficult to treat

Sources:

1. Future Markets Technology Report, Advanced Microbial Coatings, 2023


2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245375/>

3. <https://www.cdc.gov/policy/polaris/healthtopics/hai/index.html>



# Surfaces Are a Major Source of Pathogens

>80% of common infections are transmitted by touch



DOORKNOBS, PUSHDOORS

HANDRAILS, ESCALATOR HANDLES

PUSH PLATES

ELEVATOR BUTTONS

IV POLES, BED POLES



# Nanotechnology\* to Protect Surfaces

Provides immediate & continuous  
protection of surfaces reducing  
adhesion of bacteria and virus >98%<sup>1,2, 3</sup>

When a contaminated hand touches  
a nano-coated protected surface, the  
contamination tends to stay on the hand  
and not transfer to the surface<sup>1,2,3</sup>

\*Nanotechnology licensed from McMaster University

Sources:

1. <https://pubs.acs.org/doi/10.1021/acsami.1c21476?ref=pdf>
2. <https://pubs.acs.org/doi/10.1021/acsami.3c11074>
3. <https://pubs.acs.org/doi/10.1021/acsami.2c23119?ref=pdf>

Protected with  
Nano-Coating



Unprotected



Schematic illustration comparing transfer of viruses from common high-touch surfaces from a contaminated hand.

# REPELWRAP™ Film


## Lead Product in Development to Protect High Touch Surfaces

- Provides immediate & continuous protection
- Target markets: healthcare and other high-touch, high traffic venues (i.e., transportation, schools)
- **>98%** reduction in adhesion of a Covid-19 like virus, E. coli, B. subtilis and MRSA<sup>1,2</sup>

Sources:


1. <https://pubs.acs.org/doi/10.1021/acsami.1c21476?ref=pdf>
2. <https://pubs.acs.org/doi/10.1021/acsami.3c11074>

Adhesive backing to easily apply to high touch surfaces



Schematic illustration demonstrating how REPELWRAP™ film is applied.

# REPELWRAP™ Film – How It's Made




Inspired by  
the lotus leaf



Deposition of nanoparticles  
and thermal shrinking



# REPELWRAP™ Film: Path To Commercialization



➤ Anticipate commercial production end of 2024




\* Dunmore International Corp. (“Dunmore”), a Steel Partners Holdings L.P. (NYSE:SPLP) operating company is a globally recognized film manufacturer.

# Spray Nano-Coating

## To Provide Immediate and Continuous Protection of High Touch Surfaces

- Expected to be easier to apply and expand applications
- **99.9%** reduction in MRSA and *Pseudomonas aeruginosa* and **98%** for Phi6 (a virus), due to both the repelling and antimicrobial properties of the nano-surface <sup>1</sup>
- Completing formulation work and will transfer formulation to nanoComposix\* for scale-up

1. <https://pubs.acs.org/doi/10.1021/acsami.2c23119?ref=pdf>



Schematic illustration demonstrating how spray coating is applied.




\* nanoComposix LLC, a Fortis Life Science Company (“nanoComposix”), a highly recognized nano-particles expert company

# Antimicrobial & Antiviral Nano-Coating Market Offers Significant Opportunity

Estimated global  
market revenue in 2026<sup>1</sup>

~\$1.3 Bn

~ 10% CAGR (2026-2030)



Sources: 1. Future Markets Technology Report, Advanced Microbial Coatings, 2021

# **REPELWRAP™ Film and Spray Competitive Landscape**

	REPELWRAP™ Film & Spray*	Liquid Disinfectants	Metal-Containing** and Photo-Activated Films
<b>Repels</b> bacteria, viruses, blood and liquids	+++	-	-
<b>Instantly</b> protects	+++	+++	+
<b>24-hour</b> protection	+++	-	+++
<b>Does not promote</b> bacterial resistance	+++	+	+


\* Based on McMaster testing of REPELWRAP™ film lab prototype (ACS Appl. Mater. Interfaces 2022, 14, 11068-11077; ACS Nano. 2020 Jan 28, 14 (1) 454-465; 3)

\*\* Silver, copper, zinc



# Nano-Coated Catheters

## To Reduce Infections and Blood Clots



Estimated TAM in 2033<sup>1</sup>

~\$13 Bn

~ 6.5% CAGR (2023-2033)

- ~1 M foley catheter-associated infections & ~80 K central venous catheter-associated blood clots/infections at medical cost \$0.3-\$2.3 Bn <sup>2,3</sup>
- >96% reduction in attachment of E. coli & >95% reduction in blood/fibrin networks after 24-48 hours of flow exposure <sup>4</sup>
- In prototype development

Sources:

1. <https://www.futuremarketinsights.com/reports/catheter-market>
2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992741/>
3. <https://www.infectioncontrolday.com/view/new-iv-guidelines-whats-most-critical-know>
4. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sml.202108112>

# Building A Robust Patent Portfolio

## Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof

- Chinese/ Macau Patent # ZL 202080055337.6 - Issued
- US Patent Application # 17/616,374
- Canada Patent Application # CA3142127
- Europe Patent Application # EP20819372.2
- Japan Patent Application # 2021-572059
- Hong Kong Patent Application # 62022061224.1

## Omniphobic Antimicrobial Microparticles and Compositions Thereof

- US Provisional Patent Application No 63/415078


## Methods of Making Omniphobic Materials with Hierarchical Structures and Uses Thereof

- US Patent Application Number # 18/683,578
- Canada Patent Application # CA3228893
- China Patent Application # CN202280056197.3
- Europe Patent Application # EP22857186.5
- Japan Patent Application pending

## Fluorine-free Superhydrophobic Surfaces, Methods of Making and Uses Thereof

- US Patent Application # 18/683,559
- Canada Patent Application # CA3228891
- China Patent Application # CN202280056201.6
- Europe Patent Application # EP22857178.2
- Japan Patent Application pending

# Capital Light Model




**Partner with contract manufacturers**



**Secure licensing/distribution partners;  
revenue from royalties and milestones  
on net sales**



**Maximize non-dilutive funding  
from grants**



## Growth Strategy

- Explore additional uses of nanotechnology
- Licensing/acquisition to expand product pipeline and intellectual property portfolio



# Proven Management Team



**Dr. Carolyn Myers MBA, PhD**

**President, CEO & Director**

- Principal of BioEnsemble LLC, assisting start-ups and small pharma companies in developing their business strategy and planning
- Vice President International Business Development and Alliance Management at Allergan PLC (market cap \$83 Bn, 2017, now Abbvie),
- President of Dey Laboratories and President of Mylan Technologies Inc. (market cap \$9.2 Bn, 2011, now Viatris Inc.)
- Director Hyloris Pharmaceuticals SA (BR:HYL), EyeD Pharma (private)



**Rose Zanic CPA, CA**

**CFO & Corporate Secretary**

- Over 25 years of capital markets and corporate finance expertise
- Significant experience advising Canadian public companies with financing, M&A transactions and providing public company administration.
- Previously Senior Vice-President, Corporate Finance at Wolverton Securities Ltd.
- Experience as a director and/or officer with several Canadian publicly listed companies
- Member of the TSX Venture Exchange BC Local Advisory Committee



**Tash Yousuf BSc**

**Sr. Operations Manager**

- Expertise in project and operations management
- Oversees business operations and product development, driving FendX's key projects forward
- Software Project Coordinator at Lenbrook International
- Operations Manager at Cineplex VIP Cinemas

# Board of Directors and Advisors

**Stephen Randall CPA, CGA**  
Independent Board Member  
& Audit Committee Chair

- Senior financial manager and Director with over 40 years' experience.
- Served in senior financial roles with both private, publicly traded and start-up companies in the manufacturing, telecommunications, technology, and medical device sectors.
- Former Board Member, CFO and Corporate Secretary of Titan Medical Inc (TSX: TMD and NASDAQ: TMDI)

**Pierre Soulard B.C.L., LLB, LLM**  
Independent Board Member

- Former Chief Legal Officer of CoinSmart (NEO: SMRT)
- Former partner, at Miller Thomson, a leading Canadian law firm.
- Focused on securities law, corporate finance, mergers and acquisitions and corporate governance for a wide range of national and international issuers and investors.

**Dr. Carolyn Myers MBA, PhD**  
Board Member

- FendX President & CEO

**Dr. Rohit Ramchandani**  
Advisor

- Associate Faculty, Department of International Health at Johns Hopkins Bloomberg School of Public Health
- Adjunct Assistant Professor of Health Innovation, School of Public Health & Health Systems, University of Waterloo
- Founder and CEO of Antara Global Health Advisors
- Fellow, Balsillie School of International Affairs
- Former consultant to the Independent Panel for Pandemic Preparedness & Response & Lead Author of "Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response", published in the British Medical Journal.
- Doctor of Public Health with advanced training in public health research, epidemiology, and disease control

**Dr. Tohid Didar**  
Advisor

- Awarded the University Scholar title in 2024
- Canada Research Chair in NanoBiomaterials
- Associate Professor in the Department of Mechanical Engineering, School of Biomedical Engineering and a member of the Institute of Infectious Disease Research at McMaster University
- Co-inventor of REPELWRAP™ film
- Expert in biomedical devices, bio-sensing, microfluidics, bio-functional interfaces and bio-hybrid micro/nano robots
- Postdoctoral fellow at Wyss Institute at Harvard University

# Featured in the Media

"The healthcare world needs innovative solutions like these to contribute to the global efforts to reduce the spread of potentially deadly microbes."

[usatoday.com/story/special/contributor-content/2023/11/28/how-the-lotus-leaf-inspired-the-creation-of-a-new-and-unique-innovation-in-medical-technology/71728839007/](https://www.usatoday.com/story/special/contributor-content/2023/11/28/how-the-lotus-leaf-inspired-the-creation-of-a-new-and-unique-innovation-in-medical-technology/71728839007/)



"REPELWRAP™... has the potential to make a substantial impact not only in healthcare but also in other high-traffic, high-touch point industries..."

[medium.com/authority-magazine/health-tech-dr-carolyn-myers-on-how-their-technology-can-make-an-important-impact-on-our-overall-a7b58e5790f5](https://medium.com/authority-magazine/health-tech-dr-carolyn-myers-on-how-their-technology-can-make-an-important-impact-on-our-overall-a7b58e5790f5)







"Researchers have developed a self-cleaning plastic wrap that repels bacteria and could be used to prevent the transfer of antibiotic resistant superbugs, and other forms of dangerous bacteria."

<https://www.cnn.com/2019/12/13/health/superbug-repelling-surface-intl-scli-scn/index.html>



"Their surface coatings in development provide instant and continuous protection..."

[benzinga.com/markets/penny-stocks/23/10/35217286/healthcare-associated-infection-is-one-of-the-top-ten-global-public-health-risks-fendx-is-de](https://benzinga.com/markets/penny-stocks/23/10/35217286/healthcare-associated-infection-is-one-of-the-top-ten-global-public-health-risks-fendx-is-de)



## Key Highlights

### ➤ Unique Disruptive Nanotechnology

Award-winning, patent pending nanotechnology with instant repelling properties against microbes and liquids

### ➤ Global Need for Innovative Products to Keep Surfaces Clean

Current practices are not sufficient, and infection rates continue to increase

### ➤ Accelerating Development

Lead product, REPELWRAP™ film, in pilot manufacturing runs with manufacturer

### ➤ Potential to Enter Multi-Million-Dollar Verticals

Healthcare, transportation, entertainment, arenas, schools, medical devices (i.e., catheters), etc.

### ➤ Experienced Management Team

Encompassing entrepreneurial, technical and financial expertise. Track record growing & leading businesses, R&D, product launches, finance, capital markets

### ➤ Platform Nanotechnology

Potential future revenue from spray and catheter coatings in development



# Thank You!

Reach out with any questions

[investor@fendxtech.com](mailto:investor@fendxtech.com) / [fendxtech.com](https://fendxtech.com)